TIDMEKF

EKF Diagnostics Holdings PLC

07 June 2021

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

Investor Presentations

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces that Julian Baines and Mike Salter (who will become Chief Executive Officer on 1 October 2021) will be presenting to institutional investors this week following the recent AGM statement which set out the Company's strategy for growth through to 2024.

No new price sensitive information will be disclosed, and a PDF of the presentation will be made available on the Company's website: https://www.ekfdiagnostics.com/documents-reports.html

 
EKF Diagnostics Holdings plc                                   www.ekfdiagnostics.com 
Christopher Mills, Non-executive Chairman                   Tel: +44 (0) 29 2071 0570 
Julian Baines, CEO 
Richard Evans, FD & COO 
 
N+1 Singer                                                         Tel: 020 7496 3000 
Aubrey Powell / George Tzimas / Tom 
 Salvesen 
Walbrook PR Limited                   Tel: +44 (0) 20 7933 8780 or ekf@walbrookpr.com 
Paul McManus / Lianne Cawthorne              Mob: +44 (0) 7980 541 893 / +44 (0) 7584 
                                                                              391 303

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries. EKF specialises in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analysers.

EKF specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and has custom manufacturing facilities in the across sites in the US, UK and Europe for a variety of life science products. Demand for contract manufacturing of COVID-19 sample collection tests and kits has grown dramatically during the pandemic, however the capabilities can be applied to other areas of diagnostic testing, molecular disease and forensic test manufacture.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRADKOBKCBKKAAK

(END) Dow Jones Newswires

June 07, 2021 05:10 ET (09:10 GMT)

Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Ekf Diagnostics Charts.
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Ekf Diagnostics Charts.